An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept ...

Onglyza (saxagliptin), an investigational diabetes drug under joint development by Bristol-Myers Squibb and AstraZeneca, has a cardiovascular risk profile acceptable to the FDA’s Endocrinology and ...

Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD is expected in early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims ...

The scientific benefits and legal risks of AI-driven drug discovery are consequential. But recent IP law decisions allude to a general concept that IP rights will not be awarded if AI completely or ...

BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, today announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug ...